Ohtuvayre: Dosage Form, Projected Sales, NCE-1 Date | Ensifentrine

Ohtuvayre

Ohtuvayre is an inhaled medication for adults with moderate to severe COPD, offering a new option beyond traditional steroids and bronchodilators. It targets two enzymes (PDE3 and PDE4) to both open airways and reduce lung inflammation

The information outlined in the molecule details section below would help you evaluate Para IV filing opportunities early to secure a first-to-file advantage.

Molecule Details :

Molecule Name :

Ensifentrine
Innovator :

VERONA PHARMA INC
Approval Date :

26-Jun-24
NCE-1 Date :

26-Jun-28
NCE Date :

26-Jun-29
Dosage Form :

Suspension; Inhalation
Strength :

3MG/2.5ML
Therapeutic Category :

Respiratory Agents
Revenue ($M) :

42

Year-wise Projected Sales ($M) :

2025 :

249
2026 :

540
2027 :

745
2028 :

984
2029 :

1,294
2030 :

1,677
2031 :

2,110

Looking for this molecule for your next clinical research? Access regulatory-compliant comparators with assured timelines—delivered reliably through our global network.

Why Partner With Us

Supported 1000+ clinical trials globally
Provides services across regulatory, legal & clinical research
Unmatched intelligence on batches, expiry, spacing, and historical data from innovators
Integrated CRO services as part of our offerings
Insights on global pricing for smarter clinical trial supply decisions
Global sourcing capability across US, EU, South Africa, Canada, Japan, Australia, New Zealand, Southeast Asia, and other key markets

Ohtuvayre

Molecule Details :

Year-wise Projected Sales ($M) :

Looking for this molecule for your next clinical research? Access regulatory-compliant comparators with assured timelines—delivered reliably through our global network.

Why Partner With Us

Login With

Are you sure want to logout from NCE Grid?